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Purpose: To analyse the healthcare resource consumption and related costs for the Italian 
National Health System of patients estimated to be affected by treatment-resistant depression 
(TRD) in Italy.
Patients and Methods: This was an observational retrospective study based on adminis-
trative databases, including those related to residential/semiresidential structures, of Veneto 
Region and the Local Health Unit of Bergamo in Italy (for a total of around 6 million health- 
assisted subjects). Between July 2011 and December 2017, all adult patients with a third 
antidepressant (AD) after ≥2 AD (each one with at least ≥4 weeks duration, ≥1 prescription 
at maximum dosage reported in datasheets, a grace period ≤30 days when switching AD and 
treatment maintained ≥9 months) were included. Overall and psychiatry-related healthcare 
resources consumption and related costs were estimated on a 12-months based analysis. Data 
were re-proportioned to the Italian population.
Results: We have previously estimated a total of 101,455 patients with TRD in Italy (130,049 
considering the mean maximum dosage of AD). Of them, 44.2% had at least a psychiatric 
hospitalization/visit or accessed a residential/semiresidential structure, and 31% added 
another AD or a mood stabilizer/antipsychotic drug. Patients with at least one psychiatry- 
related hospitalization increased over the number of antidepressant lines from 12.0% during 
first line up to 24.5% during fourth line. Direct healthcare costs increased from €4,405 for first 
line to €9,251 from fifth line onwards. Psychiatry-related costs went from €1,817 (first line) to 
€4,606 (fifth line onwards) and were mainly driven by residential/semiresidential structures and 
hospitalizations.
Conclusion: An upward trend with number of AD lines was observed for all healthcare 
resource utilization and consequently for all direct costs, thus indicating an increasing burden 
for patients as they move forward AD lines.
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Introduction
Depressive disorders are regarded as a worldwide public health concern.1 Around 
one-third of patients suffering from major depression experience unsatisfactory 
responses to currently approved antidepressant drugs; the rates of unsuccessful 
treatments heavily contribute to the public health burden of this condition.2,3 
Patients who fail to respond to a minimum of two different antidepressant treat-
ments administered at an adequate dose for an adequate duration within the same 
depressive episode are considered to have treatment-resistant depression (TRD).4,5 
According to the Italian guidelines, treatment strategies to manage TRD include the 
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treatment optimization, ie, increase of antidepressant 
dosage or extension of the treatment duration; switch to 
another antidepressant belonging to the same or to 
a different class; augmentation with another antidepressant 
or with other drugs as antipsychotics or mood stabilizers.6
TRD has substantial effects on patients as well as on 
their families and society at large.7 It represents 
a humanistic and clinical burden since it has been asso-
ciated with higher risk for comorbidity, increased suicid-
ality, and significant impairment of cognitive function.8
TRD is considered as the major contributor to the 
economic burden of depression for patients and for 
Healthcare Systems. Indeed, several studies showed that, 
compared to major depressive disorder, TRD requires 
greater healthcare resource utilization. TRD patients are 
twice as likely to be hospitalized or to access outpatient 
and emergency room visits.7,8 Furthermore, TRD patients 
had higher direct and indirect medical costs than non– 
treatment-resistant major depressive ones.9
To the best of our knowledge, there is a lack of data 
regarding the economic burden of TRD in Italy. In 
a previous study, we estimated the number of patients 
affected by TRD in Italy by using selected criteria to identify 
TRD according to the European Medicines Agency (EMA) 
definition.10 The present study aims to provide an evaluation 
of the healthcare resource utilization and related costs of 
patients estimated to suffer from TRD in Italy.
Methods
This observational retrospective analysis was performed 
based on real-world data from Veneto Region and the 
Local Health Unit of Bergamo in Italy (approximately 
6 million health-assisted subjects). Specifically, data were 
collected from administrative databases (beneficiaries, 
pharmaceuticals, hospitalization, outpatient specialist ser-
vices) and databases of mental residential/semiresidential 
care facilities, ie, long stay treatment structures in which 
patients can settle in (residential stay) or spend part of 
the day (semiresidential stay). Data were re-proportioned 
on the Italian Population. The patient code in each data-
base allowed electronic linkage between all different data-
bases. All the results of the analyses were produced as 
aggregated summaries, which are not possible to assign, 
either directly or indirectly, to individual patients. 
According to Italian law,11 this study has been notified to 
and approved by the local Ethics Committee of the Region 
and LHU involved: specifically, the approval was obtained 
by the Ethics Committee “Comitato Etico per la 
sperimentazione clinica delle province di Verona 
e Rovigo”, reference number 25368, approval date April, 
26, 2018 and by the Ethics Committee “Comitato Etico di 
Bergamo”, reference number 07/18, approval date 
January 30, 2018.
During July 1, 2011–December 31, 2017, all adult 
patients with TRD were included. TRD was identified by 
the presence of an antidepressant (ATC code N06A) line 
treatment after ≥2 lines responding to the following cri-
teria (Figure 1):10
● a duration of ≥4 weeks with the same treatment since 
shorter duration could be due to safety issues or 
could indicate a different diagnosis other than major 
depression;
● the presence of at least one prescription for each 
antidepressant at the maximum dosage labeled in 
the summary of product characteristics (SmPC): the 
maximum dosage was chosen to discriminate 
between different diagnoses and to ensure the identi-
fication of patients with TRD for which a dose opti-
mization/increment is suggested;6
● a grace period of ≤30 days between lines: this criter-
ion was selected in order to exclude, for instance, 
patients with well-being periods without treatment;
● if no changing occurs, treatment was maintained for 









patient has been treated for ≥ 4 weeks 
with the same treatment
MAX DOSAGE:
at least one prescription for each AD 
therapy at the maximum 
dosage labelled in the SMPC 
GRACE PERIOD ≤ 30:
a grace period of ≤ 30 days is observed 
to switch from the end of an AD and the 
beginning of the following AD
9 MONTHS:
Treatment should be maintained at least 
for 9 months
Figure 1 Criteria applied for the identification of TRD patients.
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of antidepressant treatment for a major depressive 
episode.
A treatment line was defined as the same antidepressant drug 
prescribed that met the four TRD criteria. Treatment lines 
could also be non-consecutive, ie, the presence of one or 
more antidepressant not matching TRD criteria between two 
antidepressant lines that met the four TRD criteria was 
allowed. Concomitant prescription of two antidepressants 
was considered as a single line. A switch from one antide-
pressant to another marked the beginning of a new line. The 
index date corresponded to the date of first antidepressant 
prescription during the inclusion period. Patients were fol-
lowed-up starting from index date until death or 
December 31, 2017. Patients in treatment with antipsychotics 
(ATC code: N05A) or mood stabilizers (ATC code: N03A) in 
the 6-month period prior to index date were excluded.
Augmentation was evaluated during follow-up as the 
presence of antidepressant, mood stabilizers, or antipsy-
chotics. Healthcare resource utilization was evaluated in 
terms of the presence of psychiatric-related visit (codes 
94.12.1, 94.19.1), psychiatry-related hospitalizations 
(Major Diagnostic Categories 19; diagnosis-related 
group, DRG 425-433, 523), access to residential/semiresi-
dential structures as number and percentage of patients 
using these resources among total patients identified. 
Costs analysis was performed from the perspective of the 
Italian National Health System (INHS) and comprised of 
drugs (antidepressants and other prescriptions), visits/tests 
(psychiatry-related and all-cause), psychiatry-related resi-
dential/semiresidential stays (as all costs for all services 
provided in these structures), and hospitalizations (psy-
chiatry-related, all-cause). The price at the time of pur-
chase for drug treatments was considered, while the costs 
for the hospitalizations were derived directly from DRGs 
codes; outpatient specialist visits costs were derived from 
regional tariffs. Mean annual costs for each resource was 
calculated as the sum of the cost for each resource between 
two consequent antidepressant lines divided by the sum of 
years between two consequent lines and divided by the 
total number of patients. Mean annual residential/semire-
sidential and psychiatry-related hospitalization costs were 
also calculated among patients in each antidepressant line 
and among patients that actually accessed into a structure/ 
hospital in each antidepressant line. A sensitivity analysis 
of healthcare costs was performed by considering 
a duration of ≥6 weeks instead of a duration of ≥4 weeks 
with the same treatment, in line with the literature.12,13
ANOVA test was used to compare mean annual costs. 
Statistical significance between antidepressant lines was 
accepted at p<0.05.
Results
As previously reported, by projecting data on the Italian 
population, 101,455 patients were estimated to be affected 
by TRD according to the inclusion/exclusion criteria 
applied and were included in the analysis.10 Of them, 
63,842 were estimated in the age-range 18–64, and 
37,613 were ≥65 years old. Patients were prescribed at 
a mean dosage which represented 84.2% of the maximum 
dosage. When this proportion was considered as criterium, 
130,049 patients were identified (81,836 in the age range 
18–64 and 48,213 ≥65).
Overall, 44.2% of TRD patients had at least 
a psychiatric hospitalization or visit or accessed 
a residential/semiresidential structure, and 31% also 
required an augmentation. Patient’s distribution according 
to psychiatric-related resources are reported in Figure 2. 
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TRD patients with psychiatric resource utilization
N= 44,868
TRD patient with maximum dosage criterion
N=101,455




TRD patients with psychiatric resource utilization
N= 54,514
TRD patient with 84.2% of maximum dosage criterion
N= 130,049
Figure 2 Italian projection of patient distribution according to psychiatric-related resource utilization considering (A) maximum dosage labelled in SMPC and (B) the ratio 
between mean dosage prescribed/maximum dosage labeled in SMPC.
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The proportion of patients with at least one psychiatry- 
related hospitalization increased over the number of anti-
depressant lines: 12.0% during the first line, 17.4% during 
the second one, 18.7% during the third one, up to 24.5% 
during the fourth line (Figure 3); 13.1% of patients with 
more antidepressant lines experienced at least 
a psychiatry-related hospitalization. However, this latter 
data must be interpreted considering that patients may 
not have ended the last line at the end of data availability, 
therefore it could be underestimated. Mean annual number 
of hospitalizations per patient ranged from 0.14 (first line) 
to 0.30 (fourth line).
A statistically significant increase of overall yearly costs 
from €4,405 for the first line to €9,251 for the fifth line 
onwards was observed (p<0.001). All-cause hospitalizations 
were the major determinants of the total annual costs and 
went from €1,345 for the first line to €2,582 for the fifth line 
onwards (p<0.001). The increments were particularly evident 
for total costs psychiatry-related, from €1,817 (first line) to 
























Figure 3 Psychiatry-related hospitalizations according to antidepressant lines.
Figure 4 Mean annual all-cause and psychiatry-related costs according to antidepressant lines. 
Notes: All comparisons were statistically significant (p<0.001). The red box highlights the psychiatry-related costs. Overall psychiatry-related costs for each antidepressant 
line is reported next to red brackets.
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(p<0.001). Psychiatry-related yearly costs were mainly dri-
ven by residential/semiresidential structures, that ranged 
from to €971 (first line) to €3,177 (fifth line onwards) 
(p<0.001). A further analysis was performed to specifically 
evaluate the annual costs for residential/semiresidential 
structures and for psychiatry-related hospitalization per 
patient that actually was in each antidepressant line. 
Number/percentage for each line projected to the Italian 
population is reported in Supplementary Tables 1 and 2. 
Among patients in each line, mean annual costs related to 
residential/semiresidential structure for TRD (starting from 
the third antidepressant line) increased from €2,030 for 
patients in the third antidepressant line to €9,305 for patients 
prescribed their fifth or more antidepressant line (p<0.001) 
(Figure 5). The 34.1% of TRD patients identified were esti-
mated to have accessed a residential/semiresidential 
structure. Costs were also evaluated among patients that 
actually accessed a residential/semiresidential structure stra-
tified by antidepressant lines: in this case, the annual costs for 
these structures rose from €7,556 (first line) to €21,462 (fifth 
line onwards) (p<0.001) and mean annual costs for residen-
tial/semiresidential structures was €11,866 per patient, and 
€14,563 per TRD patient (from third line onwards). Overall, 
29% of patients had at least one access to hospital for psy-
chiatry causes. Mean annual costs for TRD (starting from the 
third antidepressant line) related to psychiatry hospitalization 
for patients that actually had such hospitalization increased 
from €6,301 for patients in the third antidepressant line to 
€8,321 for patients prescribed their fifth or more antidepres-
sant line (p<0.001) (Figure 6), for a mean annual cost of 
€6,135 per hospitalized patient and €6,860 per hospitalized 














1 2 3 4 5+
€
antidepressant lines
Costs among patients in each AD line Costs among patients with residential/semiresidential structures
Figure 5 Mean annual costs of residential/semiresidential structures according to antidepressant lines. 




















1 2 3 4 5+
€
antidepressant lines
Costs among patients in each AD line Costs among patients with hospitalizations
Figure 6 Mean annual costs of psychiatry-related hospitalizations according to antidepressant lines. 
Notes: All comparisons were statistically significant (p<0.001). The number of patients within each lines are reported in Supplementary Table 2.
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In the previous study,10 we observed that mean of lines 
duration exceeded the threshold of ≥4 weeks, and that the 
estimation of TRD patients considering the treatment dura-
tion of ≥6 weeks with the same antidepressant as criterion 
was 97,223, ie, the overall sample changed in a negligible 
rate of patients. In the present study, we have calculated in 
a sensitivity analysis the healthcare costs for such patients 
(Supplementary Figures 1 and 2), obtaining similar values 
to those reported for the threshold of ≥4 weeks.
Discussion and Conclusion
To date, few data are reported on TRD burden in Italy. In 
the present study, we provided an estimation of healthcare 
resource consumption and related costs per TRD patient 
for INHS in real-world settings of clinical practice. Our 
findings highlighted a growing trend of direct healthcare 
costs, both all-cause and psychiatry-related, with the 
increase in the number of antidepressant treatment lines.
In literature it has been widely reported that TRD patients 
incur more healthcare expenses and resource use compared 
to patient with non-TRD depressive syndromes,9,14 and the 
economic burden significantly increases with the level of 
resistance.13,15 This tendency was observed in our study as 
well, by comparing costs over different number of antide-
pressant lines. A possible explanation is given by the incre-
ment of morbidity during the depression state that require 
further treatments and leads to higher utilization of medical 
resource and subsequently to higher costs.15
Although drug therapy had a significant impact on the 
total expenditure, hospitalizations and residential/semiresi-
dential structures were the major determinant of the overall 
costs. Given the lack of data on the economic impact of 
TRD in Italy, it is difficult to compare our results with 
international studies, given the different Healthcare 
Systems and different access to healthcare resources. 
However, several studies observed hospitalization costs to 
consistently increase disproportionately to other costs.15,16
Our cohort of patients reflected real clinical practice, 
and the results must be interpreted taking into account the 
limitations related to the observational nature of the study, 
which was based on data collected from administrative 
databases. First, there is not a consensus definition for 
TRD, therefore we could have over- or underestimated 
the number of TRD patients. Furthermore, out-of-pocket 
costs (ie, private psychiatric visits or private long-stay 
psychiatric structure) could not be evaluated as adminis-
trative databases contain data on healthcare resources 
reimbursed by INHS.
In conclusion, all healthcare costs estimated in the 
present analysis significantly increased with number of 
antidepressant lines, highlighting the greater need of 
resources utilization as patients move forward lines. The 
subsequent high economic impact further contributes to 
the overall burden of TRD.
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